Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells

Zhu YueKun; Zhao XianQi; Wang DaWei; Zhang Wei; Tian MaoLin; Li ZhengTian; Zhao Long; Li Chao; Jiang HongChi

doi:10.3969/j.issn.1001-5256.2018.12.021

Issue 12

Dec. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(12): 2614-2618

PDF( 1819 KB)

Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells

DOI: 10.3969/j.issn.1001-5256.2018.12.021

Research funding:

Published Date: 2018-12-20

Abstract

Abstract

Objective To investigate the antitumor effect of cyclooxygenase-2 (COX-2) antisense RNA combined with celecoxib on hepatoma CBRH7919 cells. Methods The effect of celecoxib on in vitro proliferative activity, cell cycle, and apoptosis of hepatoma cell lines CBRH7919, CBRH7919-E, and CBRH7919-A (transfected with COX-2 antisense gene segment) were observed. MTT assay, cell cycle analysis, and RT-PCR were used to evaluate the change in in vitro proliferation of hepatoma cell lines. A multivariate analysis of variance was used for comparison of continuous data between groups, and the SNK-q test was used for further comparison between two groups.Results After the treatment with celecoxib, CBRH7919-A cells had a significant reduction in growth rate compared with CBRH7919 and CBRH7919-E cells (F = 38. 303, P < 0. 01) , in a time-and dose-dependent manner (F = 162. 638 and 22. 666, both P < 0. 01) .Celecoxib significantly increased the proportion of cells in G0/G1 phase and had a marked inhibitory effect on cells in S phase in a dose-dependent manner (F = 32. 515, P < 0. 01) , while there was no significant change in the proportion of cells in G2/M phase. Compared with CBRH7919 and CBRH7919-E cells, CBRH7919-A cells were more sensitive to celecoxib (F = 1219. 506, P < 0. 01) . After the treatment with celecoxib at different concentrations (40 and 80 μmol/L) , all three groups had a significant increase in cell apoptosis (all P <0. 01) , and there was no significant difference in apoptosis between the three groups (P > 0. 05) . Conclusion COX-2 antisense RNA combined with celecoxib can inhibit the in vitro growth and proliferation and cell cycle of hepatoma CBRH7919 cells, promote apoptosis, and thus exert a potential therapeutic effect on hepatoma cells.
- carcinoma, hepatocellular,
- cyclooxygenase 2,
- cyclooxygenase 2 inhibitors,
- cell proliferation,
- apoptosis

FullText(HTML)

References(18)

References

[1] ZHAO XQ, JIANG HC, ZOU YN, et al. Experimental study on the inhibitory effect of selexib on hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2006, 12 (5) :350-351. (in Chinese) 赵宪琪, 姜洪池, 邹亚男, 等.塞莱昔布对肝癌细胞抑制作用的实验研究[J].中华肝胆外科杂志, 2006, 12 (5) :350-351.

[2] ZHAO XQ, JIANG HC, PIAO DX, et al. COX-2 antisense RNA inhibit the proliferation of hepatocellular carcinoma cells study[J]. Chin J Hepatobiliary Surg, 2009, 15 (12) :912-916. (in Chinese) 赵宪琪, 姜洪池, 朴大勋, 等. COX-2反义RNA抑制肝癌细胞增殖的实验研究[J].中华肝胆外科杂志, 2009, 15 (12) :912-916.

[3] BONNVAS S, TSANTES A, DROSOS T, et al. Cancer chemoprevention:A summary of the current evidence[J]. Anticancer Res, 2008, 28 (3B) :1857-1866.

[4] CHENG J, JMANISHI H, AMURO Y, et al. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines[J]. Int J Cancer, 2002, 99 (5) :755-761.

[5] CUI W, YU CH, HU KQ, et al. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells[J]. Clin Cancer Res, 2005, 11 (22) :8213-8221.

[6] MAIERT, SCHILINGK, SCHMIDT R, et al. Cyclooxygenase-2 (COX-2) -dependent and-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells[J]. Biochem Pharmacol, 2004, 67 (8) :1469-1478.

[7] PATAL V, DUNN M, SOROKIN A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2[J]. J Biol Chem, 2002, 277:38915-38920.

[8] KUROKAWA T, KOHNO K, NAGAI K, et al. Antisense RNA transcripts in the blood may be novel diagnostic markers for colorectal cancer[J]. Oncol Lett, 2017, 14 (3) :3487-3493.

[9] LAI YX, XU P, LIU J, et al. Decreased expression of the long non-coding RNA MLLT4 antisense RNA 1 is a potential biomarker and an indicator of a poor prognosis for gastric cancer[J]. Oncol Lett, 2017, 14 (3) :2629-2634.

[10] MIN SN, WEI T, WANG XT, et al. Clinicopathological and prognostic significance of homeobox transcript antisense RNA expression in various cancers:A meta-analysis[J]. Medicine (Baltimore) , 2017, 96 (23) :e7084.

[11] SAVITSKA M, ONISHCHENKO G. Mechanisms of Apoptosis[J].Biochemistry Mosc, 2015, 80 (11) :1393-1405.

[12] LI Q, PENG J, LIU T, et al. Effects of celecoxib on cell apoptosis and Fas, Fas L and Bcl-2 expression in a BGC-823 human gastric cancer cell line[J]. Exp Ther Med, 2017, 14 (3) :1935-1940.

[13] KUMAR V, KAUR K, GUPTA G, et al. Developments in synthesis of the anti-inflammatory drug, celecoxib:A review[J]. Recent Pat Inflamm Allergy Drug Discov, 2013, 7 (2) :124-134.

[14] CHEN J, SHENG P, ZHANG XC, et al. Efficacy and safety profile of celecoxib for treating advanced cancers:A meta-analysis of 11randomized clinical trials[J]. Clin Ther, 2014, 36 (8) :1253-1263.

[15] CHE XH, CHEN CL, YE XL, et al. Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro[J]. Oncol Rep, 2016, 35 (3) :1680-1688.

[16] WINTHER T, TORP S. The anti-apoptotic protein survivin can improve the prognostication of meningioma patients[J]. PLo S One, 2017, 12 (9) :e0185217.

[17] YU TT, LAO XZ, ZHENG H, et al. Influencing COX-2 Activity by COX related pathways in inflammation and cancer[J]. Mini Rev Med Chem, 2016, 16 (15) :1230-1243.

[18] MORIA L, CASTELLSA. Cyclooxygenase as a Target for Colorectal Cancer Chemprevention[J]. Curr Drug, 2011, 12 (13) :1888-1894.

Relative Articles

[1]	Huimin LI, Yizhuo CHEN, Rui ZHAO, Xiao HUANG, Fei HUANG, Huanhuan LI. A comparative analysis of the hemogram and myelogram of patients with liver cirrhosis and the advantages and disadvantages of splenectomy[J]. Journal of Clinical Hepatology, 2023, 39(9): 2217-2224. doi: 10.3969/j.issn.1001-5256.2023.09.028
[2]	Yitong BAI, Lianjie LIN, Dongmei PEI. Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(4): 805-809. doi: 10.3969/j.issn.1001-5256.2022.04.013
[3]	Mou SiYu, Yang Zhe, Wu LiQun, Qiu Xuan, Guo JiaMing. Predictive factors for portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 106-111. doi: 10.3969/j.issn.1001-5256.2018.01.022
[4]	Ao Fei, Chen WeiQing. Research advances in portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(3): 631-634. doi: 10.3969/j.issn.1001-5256.2018.03.043
[5]	Bao WenChun, Qi XingShun, Tang ShanHong, Li HongYu. An excerpt of the Japanese research group on IPH: diagnosis and treatment guidelines for aberrant portal hemodynamics (2017)[J]. Journal of Clinical Hepatology, 2017, 33(3): 432-434. doi: 10.3969/j.issn.1001-5256.2017.03.006
[6]	Liu ShuYan. Association between cerebral hemodynamic changes and neonatal hyperbilirubinemia[J]. Journal of Clinical Hepatology, 2017, 33(10): 1974-1976. doi: 10.3969/j.issn.1001-5256.2017.10.025
[7]	Tang HanQiu. Clinical effect of laparoscopic splenectomy combined with esophagogastric devascularization in treatment of liver cirrhosis with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(9): 1743-1746. doi: 10.3969/j.issn.1001-5256.2016.09.022
[8]	Liang XiaoHua, Zhang Feng, Zhu GeYuZheng. Effect of transjugular intrahepatic portosystemic shunt combined with splenic artery embolization on hepatic hemodynamics and liver function in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2112-2117. doi: 10.3969/j.issn.1001-5256.2016.11.021
[9]	Bao HanKang, Wei XiuLi. Clinical effects of hand-assisted laparoscopic vs open splenectomy combined with pericardial devascularization the treatment of portal hypertension in liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 431-433. doi: 10.3969/j.issn.1001-5256.2015.03.027
[10]	Yang ZhengMao, Zhang LingYi. Risk factors for portal vein thrombosis following splenectomy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(7): 1173-1175. doi: 10.3969/j.issn.1001-5256.2015.07.044
[11]	Duan LiWei, Sun Han, Chen YongSheng, Tian YueLi, Li DongFu. Hemodynamic effects of partial splenic artery embolization in patients with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2013, 29(2): 142-145.
[12]	Shang JianZhong, Ma LongFei, Ma HongWei, Zhao QiuFang, Zhao LinHua, Li XiaoFei, Fan YanFeng, Zhang SuE. Effect of autologous bone marrow- derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 848-851. doi: 10.3969/j.issn.1001-5256.2013.10.012
[14]	Jin HongHui, Ding XiaoHong. ROC curve analysis of blood platelet and hyaluronic acid levels for diagnosing cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(6): 456-458.
[15]	Gao Lei, Jing Xiang, Zhao XinMin, Zuo YanLing. Hemodynamics of portal vein in cirrhotic patients with esophageal varices[J]. Journal of Clinical Hepatology, 2010, 26(3): 297-299+305.
[16]	Liu SuLi, Feng ZhiJie, Lu: YanChun, Niu FaLiang. The clinical study of Rhizoma alismatis on hemodynamics of liver cirrohosis and portal hypertension[J]. Journal of Clinical Hepatology, 2006, 22(2): 119-120.
[17]	Qin YouJuan. Correlative study between hemodynamics of portal vein system and Child-Pugh in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 21-22.
[18]	Wang ZhiHua, Cai HanZhi, Zhao AnXin, Li XiLing, Yang HongXin. The effects of disconnection and shunt procedure on hepatic hemodynamics and function of active cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2002, 18(5): 309-310.
[19]	Dong JiLiang, Sun Jie, Ding XiuHe. Clinical observation of the effects of partial splenic embobization (PSE) on hemodynamics in 24 patients of liver cirrhosis with portal hypertention (LCPH)[J]. Journal of Clinical Hepatology, 2002, 18(6): 361-362.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	康志龙，周益民，宋燕州，张昆，苏一男，魏文平，赵新，李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 .
2.	许海明，胡永奎，梁平，钟腾猛，陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 .
3.	彭林辉，陈涛，徐云修修，王捷，陈捷，李永，黄拼搏，钟国平，陈茜，叶聪婷，陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 .
4.	李洁，李瑞娟，鲁志兵，曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 .
5.	黄乾鑫，神斌，肖晋昌，高志康，吕墩涛，李艳，徐浩，张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1472) PDF downloads(324)

Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells

DOI: 10.3969/j.issn.1001-5256.2018.12.021